Search Prime Grants

UG1EY028087

Cooperative Agreement

Overview

Grant Description
ADALIMIMAB VS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Madison, Wisconsin 53715 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 757% from $149,338 to $1,280,176.
University Of Wisconsin System was awarded ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial Cooperative Agreement UG1EY028087 worth $1,280,176 from National Eye Institute in September 2018 with work to be completed primarily in Madison Wisconsin United States. The grant has a duration of 7 years and was awarded through assistance program 93.867 Vision Research. The Cooperative Agreement was awarded through grant opportunity NEI Clinical Vision Research: Coordinating Center Grant (UG1).

Status
(Complete)

Last Modified 8/20/24

Period of Performance
9/30/18
Start Date
8/31/25
End Date
100% Complete

Funding Split
$1.3M
Federal Obligation
$0.0
Non-Federal Obligation
$1.3M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG1EY028087

Transaction History

Modifications to UG1EY028087

Additional Detail

Award ID FAIN
UG1EY028087
SAI Number
UG1EY028087-3091505083
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Awardee UEI
LCLSJAGTNZQ7
Awardee CAGE
09FZ2
Performance District
WI-02
Senators
Tammy Baldwin
Ron Johnson

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) Health research and training Grants, subsidies, and contributions (41.0) $1,429,513 100%
Modified: 8/20/24